• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance 0

Sage Therapeutics Slumps As Biogen Deal May Dampen M&A Hopes

By Kurt Osterberg · On April 20, 2018

Weakness in shares of Sage Therapeutics (SAGE) may be related to news that Biogen (BIIB) and Ionis Pharmaceuticals (IONS) have expanded their strategic collaboration through a new ten-year collaboration agreement, which may be read by some market participants as lowering the odds for M&A action related to Sage.

Under the terms of the collaboration, Biogen will pay Ionis $1B in cash, which will include $625M to purchase 11,501,153 shares of Ionis common stock at an approximately 25% cash premium, and a $375M upfront payment. On April 24, 2017, Sage announced the appointment of Michael Cloonan as Chief Business Officer. Cloonan had come to Sage from Biogen, where he worked for 14 years. On the date of that announcement, Adam Feuerstein of STAT tweeted, “$SAGE expands exec team, including former $BIIB – er Michael Cloonan as new Chief Business Officer. Stand down on $SAGE takeout for now.” More recently, on April 10, 2018, shares of Sage has spiked higher in afternoon trading amid rumors of the company canceling from a planned presentation. A spokesperson for Sage Therapeutics told The Fly the company “cancelled participation in the JPMorgan meeting due to some travel logistics issues.” In March, Canaccord analyst Sumant Kulkarni had assumed Sage Therapeutics with a Buy rating, citing among other things “a high scarcity value in its robust/ripening CNS platforms.”

In midday trading, Sage shares are down $17.90, or 10.5%, to $151.77.

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    Becoming a More Decisive Leader

  • Finance

    Let’s Talk About the “F” Word: Feedback

  • Finance

    7 Tips to Increase Productivity When Working From Home

No Comments

Leave a reply Cancel reply

Top Finance

  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce
  • Hedge Funds In The US Hedge Funds In The US
  • One Ring To Rule Them All One Ring To Rule Them All
  • Kanban vs Scrum: Understanding the Tools for Agile Success Kanban vs Scrum: Understanding the Tools for Agile Success
  • Samsung Galaxy Note 9 Review Samsung Galaxy Note 9 Review

New Posts

  • Becoming a More Decisive Leader

    Becoming a More Decisive Leader

    February 28, 2021
  • Let’s Talk About the “F” Word: Feedback

    Let’s Talk About the “F” Word: Feedback

    February 28, 2021
  • 7 Tips to Increase Productivity When Working From Home

    7 Tips to Increase Productivity When Working From Home

    February 27, 2021
  • The Door’s Open but the Ride It Ain’t Free

    The Door’s Open but the Ride It Ain’t Free

    February 27, 2021
  • 5 Smart Ways to Improve Your ROI (Plus Tools & Templates)

    5 Smart Ways to Improve Your ROI (Plus Tools & Templates)

    February 27, 2021
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018-2021 NJCEE. All Rights Reserved.